Edition:
United States

Qiagen NV (QGEN.DE)

QGEN.DE on Xetra

26.17EUR
3:55am EST
Change (% chg)

€-0.22 (-0.81%)
Prev Close
€26.39
Open
€26.17
Day's High
€26.29
Day's Low
€26.05
Volume
81,569
Avg. Vol
362,809
52-wk High
€27.67
52-wk Low
€17.76

QGEN.DE

Chart for QGEN.DE

About

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Its bioinformatics solutions... (more)

Overall

Beta: 0.49
Market Cap(Mil.): €6,224.78
Shares Outstanding(Mil.): 239.71
Dividend: --
Yield (%): --

Financials

  QGEN.DE Industry Sector
P/E (TTM): 56.17 44.51 30.50
EPS (TTM): 0.47 -- --
ROI: 3.06 -1.38 14.85
ROE: 4.59 -1.00 16.27

BRIEF-Singulex says entered into a strategic collaboration with Qiagen

* Singulex says entered into a strategic collaboration with Qiagen

Jan 10 2017

BRIEF-Qiagen submits QuantiFERON-TB Gold Plus for U.S. regulatory approval

* Qiagen submits QuantiFERON-TB Gold Plus for U.S. regulatory approval Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-Qiagen announces acquisition of OmicSoft Corporation

* Qiagen enhances bioinformatics portfolio with acquisition of OmicSoft

Jan 09 2017

BRIEF-Qiagen wants to expand with at least 2 emerging technologies per yr

* Says 2020 goal to advance tb detection with qft-plus clinical benefits

Nov 15 2016

BRIEF-Qiagen posts Q3 adj. earnings $0.29/shr

* Qiagen reports results for third quarter and first nine months of 2016

Nov 02 2016

Federal Circuit refuses Qiagen's bid to stay injunction on GeneReader sales

A federal appeals court declined Qiagen NV's bid for an emergency stay of an injunction blocking the sale of its year-old GeneReader gene-sequencing device.

Oct 27 2016

BRIEF-Qiagen shareholders approve return of about $250 mln in cash via synthetic share repurchase

* Qiagen shareholders approve return of approximately $250 million in cash to shareholders via synthetic share repurchase

Oct 26 2016

BRIEF-Qiagen shareholders approve repayment of $250 million

* Shareholders overwhelmingly approved a proposal to return approx. $250 million in cash to shareholders through a synthetic share repurchase plan

Oct 26 2016

Judge blocks sales of Qiagen gene-sequencing device

A federal judge has ordered diagnostics technology company Qiagen NV to stop selling its new GeneReader gene-sequencing device, finding that rival Illumina Inc was likely to win a patent infringement lawsuit over the device.

Sep 13 2016

BRIEF-Qiagen to return $250 mln to shareholders

* Qiagen announces plans to return approximately $250 million to shareholders via synthetic share repurchase proposal Source text for Eikon: Further company coverage:

Aug 14 2016

Earnings vs. Estimates